Home
Home  |  Log in  |  Sitemap
Quick search
2011-10-26
 

Interim Report – January to September 2011

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the first nine months of 2011.

Financial Highlights

  • Revenue for the first nine months of 2011 was SEK 20.7 (20.3) million
  • EBITDA for the period amounted to SEK -1.2 (-7.8) million while the net loss amounted to SEK -8.7 (-15.8) million
  • Cash flow from current operations before changes in working capital for the period was SEK -0.3 (-6.6) million
  • Loan conversion completed, resulting in 107 960 988 new shares (210 819 391 in total) increasing shareholders’ equity by SEK 27.0 million

Key Corporate Highlights

  • The first in human study with the HER2-binding Affibody imaging agent ABY-025 in breast cancer patients was concluded during the quarter. The study's principal investigator is Dr. Henrik Lindman, Uppsala University Hospital, and the study Sponsor is Prof. Jörgen Carlsson, Uppsala University, with support from the Swedish Cancer Society.
  • During the third quarter Affibody and GE Healthcare, a division of the General Electric Company, expanded its relationship in the field of large-scale affinity purification.
  • Furthermore, Ass. Prof. Fredrik Frejd was appointed VP Research to further strengthen the company’s focus on biopharmaceuticals.

David Bejker CEO, said: “This quarter we are especially proud of the fact that our first in human study with ABY-025 has been concluded and look forward to the San Antonio Breast Cancer Symposium in December where the study will be presented.”